ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

American Journal of Gastroenterology

Volumn 112, Issue 2, 2017, Pages 241-258

  Farraye, Francis A ^a   Melmed, Gil Y ^b   Lichtenstein, Gary R ^c   Kane, Sunanda V ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE; IMMUNOLOGIC FACTOR; VACCINE;

ANXIETY; CANCER SCREENING; CHICKENPOX; COOPERATION; CROHN DISEASE; DEPRESSION; GASTROENTEROLOGY; HEALTH MAINTENANCE ORGANIZATION; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HOUSEHOLD; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INFLUENZA VACCINATION; MELANOMA; MENINGOCOCCOSIS; NON MELANOMA SKIN CANCER; OSTEOPOROSIS; PAPILLOMAVIRUS INFECTION; PATIENT SAFETY; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; UTERINE CERVIX CANCER; VACCINATION; YELLOW FEVER; EARLY CANCER DIAGNOSIS; FEMALE; HEPATITIS, VIRAL, HUMAN; INFLAMMATORY BOWEL DISEASES; INFLUENZA, HUMAN; MALE; MENINGOCOCCAL INFECTIONS; PAPILLOMAVIRUS INFECTIONS; PNEUMOCOCCAL INFECTIONS; PREVENTIVE MEDICINE; PRIMARY HEALTH CARE; PROCEDURES; SKIN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

ANXIETY; CHICKENPOX; DEPRESSION; EARLY DETECTION OF CANCER; FEMALE; HEPATITIS, VIRAL, HUMAN; HERPES ZOSTER; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INFLUENZA, HUMAN; MALE; MELANOMA; MENINGOCOCCAL INFECTIONS; OSTEOPOROSIS; PAPILLOMAVIRUS INFECTIONS; PNEUMOCOCCAL INFECTIONS; PREVENTIVE MEDICINE; PRIMARY HEALTH CARE; SKIN NEOPLASMS; SMOKING CESSATION; UTERINE CERVICAL NEOPLASMS; VACCINES;

EID: 85009215293     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.537     Document Type: Review

References (184)

1. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
2. Selby L, Kane S, Wilson J et al. Receipt of preventive health services by IBD patients is signifcantly lower than by primary care patients. Inflamm Bowel Dis 2008; 14: 253-8.
3. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis 2009; 15: 1399-409.
4. General Health Maintenance Fact Sheet. Available at www.ccfa.org, 2009.
5. Desalermos AP, Farraye FA, Wasan SK. Vaccinating the Inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2015; 9: 91-102.
6. Wasan SK, Coukos JA, Farraye FA. Vaccinating the Inflammatory bowel disease patient: Defciencies in gastroenterologists knowledge. Inflamm Bowel Dis 2011; 17: 2536-40.
7. Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis 2012; 18: 34-40.
8. Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventive care for Inflammatory bowel disease patients? Dig Dis Sci 2011; 56: 819-24.
9. Melmed GY. Immunizations and IBD: Whose responsibility is it? If I'm the prescribing doctor, shouldn't it be mine? Inflamm Bowel Dis 2012; 18: 41-2.
10. Rubin LG, Levin MJ, Ljungman P et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58: e44-100.
11. Rubin LG, Levin MJ, Ljungman P et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: 309-18.
12. Malhi G, Rumman A, Tanabalan R et al. Vaccination in Inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis 2015; 9: 439-44.
13. Wasan SK, Baker SE, Skolnik PR et al. A practical guide to vaccinating the Inflammatory bowel disease patient. Am J Gastroenterol 2010; 105: 1231-8.
14. Melmed GY, Ippoliti AF, Papadakis KA et al. Patients with Inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-40.
15. Sands BE, Cuflari C, Katz J et al. Guidelines for immunizations in patients with Inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 677-92.
16. Long MD, Gulati A, Wohl D et al. Immunizations in pediatric and adult patients with Inflammatory bowel disease: a practical case-based approach. Inflamm Bowel Dis 2015; 21: 1993-2003.
17. Kim DK, Bridges CB, Harriman KH et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older-United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 91-2.
18. Kim DK, Bridges CB, Harriman KH et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med 2016; 164: 184-94.
19. Cleveland NK, Rodriquez D, Wichman A et al. Many Inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci 2016; 61: 2972-6.
20. Loras C, Saro C, Gonzalez-Huix F et al. Prevalence and factors related to hepatitis B and C in Inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57-63.
21. Lester R, Lu Y, Tung J. Survey of immunization practices in patients with Inflammatory bowel disease among pediatric gastroenterologists. J Pediatr Gastroenterol Nutr 2015; 61: 47-51.
22. Rahier JF, Papay P, Salleron J et al. H1N1 vaccines in a large observational cohort of patients with Inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011; 60: 456-62.
23. Dotan I, Werner L, Vigodman S et al. Normal response to vaccines in Inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2012; 18: 261-8.
24. Parker S, Chambers White L, Spangler C et al. A quality improvement project signifcantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis 2013; 19: 1809-14.
25. Reich JS, Miller HL, Wasan SK et al. influenza and pneumococcal vaccination rates in patients with Inflammatory bowel disease. Gastro Hepatol 2015; 11: 396-402.
26. Christensen KR, Steenholdt C, Buhl SS et al. Systematic information to health-care professionals about vaccination guidelines improves adherence in patients with Inflammatory bowel disease in anti-TNFalpha therapy. Am J Gastroenterol 2015; 110: 1526-32.
27. Ahmed S, Siegel CA, Melmed GY. Implementing quality measures for Inflammatory bowel disease. Curr Gastroenterol Rep 2015; 17: 14.
28. Panes J, O'Connor M, Peyrin-Biroulet L et al. Improving quality of care in Inflammatory bowel disease: what changes can be made today? J Crohns Colitis 2014; 8: 919-26.
29. Tinsley A, Williams E, Liu G et al. The incidence of influenza and influenza-related complications in Inflammatory bowel disease patients across the united states. Am J Gastroenterol 2013; 108: S554.
30. Stobaugh DJ, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with Inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol 2013; 6: 43-9.
31. Beck CR, McKenzie BC, Hashim AB et al. influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. influenza Other Respir Viruses 2013; 7 (Suppl 2): 72-5.
32. Wasan SK, Calderwood AH, Long MD et al. Immunization rates and vaccine beliefs among patients with Inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis 2014; 20: 246-50.
33. Crawford NW, Catto-Smith AG, Oliver MR et al. An Australian audit of vaccination status in children and adolescents with Inflammatory bowel disease. BMC Gastroenterol 2011; 11: 87.
34. Burger D, Blad W, White L et al. Uptake in the UK of vaccination recommendations in Inflammatory bowel disease (IBD). J Crohn's Colitis 2012; 6: S108.
35. Halliday N, Murray S, Parkes G et al. Compliance with guidelines on viral screening and vaccination of patients with Inflammatory bowel disease (IBD). Gut 2012; 61: A234-5.
36. Hinojosa J, Gisbert JP, Gomollon F et al. Adherence of gastroentero logists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain. J Crohn's Colitis 2012; 6: 763-70.
37. Morace F, Amalf G, Caravelli G et al. Vaccination status in Inflammatory bowel disease patients. Dig Liver Dis 2013; 45: S93.
38. Risager Christensen K, Steenholdt C, Schnoor Buhl S et al. Vaccination routines during anti-TNF treatment in IBD: Do patients adhere to ECCO's guidelines? J Crohn's Colitis 2014; 8: S189.
39. Song HK, Jung SA, Cha JM et al. Adherence to quality measures for Inflammatory bowel disease in Korea: questionnaire study based on American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance Measures Set. J Crohn's Colitis 2014; 8: S304-5.
40. Wilckens V, Kannengiesser K, Hoxhold K et al. The immunization status of patients with IBD is alarmingly poor before the introduction of specifc guidelines. Scand J Gastroenterol 2011; 46: 855-61.
41. Jung YS, Park JH, Kim HJ et al. Insufcient knowledge of korean gastroenterologists regarding the vaccination of patients with Inflammatory bowel disease. Gut Liver 2014; 8: 242-7.
42. Agarwal N, Ollington K, Kaneshiro M et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 2012; 30: 1413-24.
43. Andrisani G, Frasca D, Romero M et al. Immune response to influenza A/H1N1 vaccine in Inflammatory bowel disease patients treated with anti TNF-alpha agents: Effects of combined therapy with immunosuppressants. J Crohn's Colitis 2013; 7: 301-7.
44. Gelinck LB, van der Bijl AE, Beyer WE et al. The Effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-6.
45. Hagihara Y, Ohfuji S, Watanabe K et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with Inflammatory bowel disease. J Crohn's Colitis 2014; 8: 223-33.
46. Lu Y, Jacobson DL, Ashworth LA et al. Immune response to influenza vaccine in children with Inflammatory bowel disease. Am J Gastroenterol 2009; 104: 444-53.
47. Mamula P, Markowitz JE, Piccoli DA et al. Immune response to influenza vaccine in pediatric patients with Inflammatory bowel disease. Clin Gastro enterol Hepatol 2007; 5: 851-6.
48. deBruyn JC, Hilsden R, Fonseca K et al. Immunogenicity and safety of influenza vaccination in children with Inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 25-33.
49. Cullen G, Bader C, Korzenik JR et al. Serological response to the 2009 H1N1 influenza vaccination in patients with Inflammatory bowel disease. Gut 2012; 61: 385-91.
50. Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of Inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci 2015; 60: 2446-53.
51. deBruyn J, Fonseca K, Ghosh S et al. Immunogenicity of influenza vaccine for patients with Inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis 2015; 22: 638-47.
52. Melmed GY. Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol 2012; 107: 141-2.
53. Melmed GY. Vaccination strategies for patients with Inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009; 15: 1410-6.
54. Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57 (RR-7): 1-60.
55. Harper SA, Fukuda K, Cox NJ et al. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52 (RR-13): 1-8.
56. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23, quiz 24.
57. Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in Inflammatory bowel disease. J Crohn's Colitis 2014; 8: 443-68.
58. Rufo PA, Denson LA, Sylvester FA et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55: 93-108.
59. Rahier JF, Moreels T, De Munter P et al. Prevention of opportunistic infections in patients with Inflammatory bowel disease and implications of the ECCO consensus in Belgium. Acta Gastroenterol Belg 2010; 73: 41-5.
60. Melmed GY, Siegel CA, Spiegel BM et al. Quality indicators for Inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis 2013; 19: 662-8.
61. Long MD, Martin C, Sandler RS et al. Increased risk of pneumonia among patients with Inflammatory bowel disease. Am J Gastroenterol 2013; 108: 240-8.
62. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with Inflammatory bowel diseases. J Crohn's Colitis 2013; 7: 107-12.
63. Kantso B, Simonsen J, Hoffmann S et al. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a Nationwide Danish Cohort Study 1977-2013. Am J Gastroenterol 2015; 110: 1582-7.
64. Melmed GY, Agarwal N, Frenck RW et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with Inflammatory bowel disease. Am J Gastroenterol 2010; 105: 148-54.
65. Fiorino G, Peyrin-Biroulet L, Naccarato P et al. Effects of immunosuppression on immune response to pneumococcal vaccine in Inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012; 18: 1042-7.
66. Banaszkiewicz A, Targonska B, Kowalska-Duplaga K et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with Inflammatory bowel disease. Inflamm Bowel Dis 2015; 21: 1607-14.
67. Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013; 369: 255-63.
68. Harpaz R, Ortega-Sanchez IR, Seward JF et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57 (RR-5): 1-30, quiz CE2-4.
69. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in Inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2392-403.
70. Tsai SY, Yang TY, Lin CL et al. Increased risk of varicella zoster virus infection in Inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract 2015; 69: 228-34.
71. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with Inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-90.
72. Long MD, Martin C, Sandler RS et al. Increased risk of herpes zoster among 108 604 patients with Inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 420-9.
73. Hales CM, Harpaz R, Ortega-Sanchez I et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep 2014; 63: 729-31.
74. Zhang J, Xie F, Delzell E et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-9.
75. Lal H, Cunningham AL, Godeaux O et al. Efcacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087-96.
76. Cohen JI. A new vaccine to prevent herpes zoster. N Engl J Med 2015; 372: 2149-50.
77. Ansari F, Baker RD, Patel R et al. Varicella immunity in Inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53: 386-8.
78. Kopylov U, Levin A, Mendelson E et al. Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. Aliment Pharmacol Ther 2012; 36: 145-50.
79. Marin M, Guris D, Chaves SS et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-4): 1-40.
80. Lu Y, Bousvaros A. Varicella vaccination in children with Inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 2010; 50: 562-5.
81. Visser LG. The immunosuppressed traveler. Infect Dis Clin North Am 2012; 26: 609-24.
82. MacNeil JR, Rubin L, Folaranmi T et al. Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 1171-6.
83. Waszczuk K, Waszczuk E, Mulak A et al. 'cocoon immunization strategy' among patients with Inflammatory bowel disease. Eur J Gastroenterol Hepatol 2015; 27: 249-53.
84. Wyant T, Leach T, Sankoh S et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2015; 64: 77-83.
85. Milanovic M, Stojanovich L, Djokovic A et al. influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med 2013; 229: 29-34.
86. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60: 13-15.
87. National Center for Immunization and Respiratory Diseases. General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60: 1-64.
88. Loras C, Gisbert JP, Minguez M et al. Liver dysfunction related to hepatitis B and C in patients with Inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-6.
89. Coates T, Wilson R, Patrick G et al. Hepatitis B vaccines: assessment of the seroprotective efcacy of two recombinant DNA vaccines. Clin Ther 2001; 23: 392-403.
90. Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013; 10: 277-85.
91. Marin AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in Inflammatory bowel disease. World J Gastroenterol 2015; 21: 11273-81.
92. Gisbert JP, Menchen L, Garcia-Sanchez V et al. Comparison of the Effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with Inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 1379-85.
93. Publication WHO. Hepatitis B vaccines: WHO position paper-recommendations. Vaccine 2010; 28: 589-90.
94. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355: 561-5.
95. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-44 e3.
96. Reddy KR, Beavers KL, Hammond SP et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-9, quiz e16-7.
97. Practice Bulletin No. 157: Cervical Cancer Screening and Prevention. Obstet Gynecol 2016; 127: e1-20.
98. Long MD, Porter CQ, Sandler RS et al. Suboptimal rates of cervical testing among women with Inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 549-53.
99. Singh H, Nugent Z, Demers AA et al. Screening for cervical and breast cancer among women with Inflammatory bowel disease: a populationbased study. Inflamm Bowel Dis 2011; 17: 1741-50.
100. Magro F, Peyrin-Biroulet L, Sokol H et al. Extra-intestinal malignancies in Inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientifc Workshop (III). J Crohns Colitis 2014; 8: 31-44.
101. Allegretti JR, Barnes EL, Cameron A. Are patients with Inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis 2015; 21: 1089-97.
102. Rungoe C, Simonsen J, Riis L et al. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol 2015; 13: 693-700 e1.
103. Mikocka-Walus A, Knowles SR, Keefer L et al. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with Inflammatory bowel diseases. Inflamm Bowel Dis 2016; 22: 752-62.
104. Mittermaier C, Dejaco C, Waldhoer T et al. Impact of depressive mood on relapse in patients with Inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004; 66: 79-84
105. Persoons P, Vermeire S, Demyttenaere K et al. The impact of major depressive disorder on the short-and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther 2005; 22: 101-10.
106. Calvet X, Gallardo O, Coronas R et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis 2006; 12: 692-6.
107. Mikocka-Walus AA, Turnbull DA, Moulding NT et al. Does psychological status Influence clinical outcomes in patients with Inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: an observational cohort prospective study. Biopsychosoc Med 2008; 2: 11.
108. Bitton A, Dobkin PL, Edwardes MD et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008; 57: 1386-92.
109. Ananthakrishnan AN, Gainer VS, Cai T et al. Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis. Am J Gastroenterol 2013; 108: 594-601.
110. Langhorst J, Hofstetter A, Wolfe F et al. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. Inflamm Bowel Dis 2013; 19: 2380-6.
111. Mawdsley JE, Macey MG, Feakins RM et al. The Effect of acute psychologic stress on systemic and rectal mucosal measures of Inflammation in ulcerative colitis. Gastroenterology 2006; 131: 410-9.
112. Mikocka-Walus AA, Turnbull DA, Moulding NT et al. Antidepressants and Inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006; 2: 24.
113. Goodhand JR, Wahed M, Mawdsley JE et al. Mood disorders in Inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis 2012; 18: 2301-9.
114. Mikocka-Walus AA, Gordon AL, Stewart BJ et al. The role of antidepressants in the management of Inflammatory bowel disease (IBD): a short report on a clinical case-note audit. J Psychosom Res 2012; 72: 165-7.
115. Nigro G, Angelini G, Grosso SB et al. Psychiatric predictors of noncompliance in Inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001; 32: 66-8.
116. Ediger JP, Walker JR, Graff L et al. Predictors of medication adherence in Inflammatory bowel disease. Am J Gastroenterol 2007; 102: 1417-26.
117. Keller W, Pritsch M, Von Wietersheim J et al. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the German Prospective Multicenter Psychotherapy Treatment study on Crohn's Disease. J Psychosom Res 2004; 56: 687-96.
118. Deter HC, Keller W, von Wietersheim J et al. Psychological treatment may reduce the need for healthcare in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13: 745-52.
119. Timmer A, Preiss JC, Motschall E et al. Psychological interventions for treatment of Inflammatory bowel disease. Cochrane Database Syst Rev 2011, CD006913.
120. National Cancer Institute. What you need to know about melanoma and other skin cancers U.S. Department of Health and Human Services: 2010.
121. Cancer Facts & Figures. American Cancer Society 2015.
122. McPherson M, Elwood M, English DR et al. Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol 2006; 54: 783-92.
123. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010; 60: 301-16.
124. Torres J, Buche S, Delaporte E et al. Skin side Effects of Inflammatory bowel disease therapy. Inflamm Bowel Dis 2013; 19: 1086-98.
125. Singh S, Nagpal SJ, Murad MH et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 210-8.
126. Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49: 506-9.
127. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40 (2 Pt 1): 177-86.
128. Lampros TD, Cobanoglu A, Parker F et al. Squamous and basal cell carcinoma in heart transplant recipients. J Heart Lung Transplant 1998; 17: 586-91.
129. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17, quiz 8-20.
130. Silverberg MJ, Leyden W, Warton EM et al. HIV infection status, immunodefciency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013; 105: 350-60.
131. Fortina AB, Piaserico S, Caforio AL et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004; 140: 1079-85.
132. Ramsay HM, Reece SM, Fryer AA et al. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation 2007; 84: 437-9.
133. Brewer JD, Colegio OR, Phillips PK et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145: 1391-6.
134. Long MD, Martin CF, Pipkin CA et al. Risk of melanoma and nonmelanoma skin cancer among patients with Inflammatory bowel disease. Gastroenterology 2012; 143: 390-9 e1.
135. Farrell RJ, Ang Y, Kileen P et al. Increased incidence of non-Hodgkin's lymphoma in Inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514-9.
136. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904.
137. Masunaga Y, Ohno K, Ogawa R et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in Inflammatory bowel disease. Ann Pharmacother 2007; 41: 21-8.
138. Askling J, Fahrbach K, Nordstrom B et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-30.
139. Ekbom A, Helmick C, Zack M et al. Extracolonic malignancies in Inflammatory bowel disease. Cancer 1991; 67: 2015-9.
140. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of Inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
141. Jess T, Winther KV, Munkholm P et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004; 19: 287-93.
142. Long MD, Herfarth HH, Pipkin CA et al. Increased risk for non-melanoma skin cancer in patients with Inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.
143. Mellemkjaer L, Olsen JH, Frisch M et al. Cancer in patients with ulcerative colitis. Int J Cancer 1995; 60: 330-3.
144. Pedersen N, Duricova D, Elkjaer M et al. Risk of extra-intestinal cancer in Inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010; 105: 1480-7.
145. Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for Inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8. e1-5.
146. Singh H, Nugent Z, Demers AA et al. Increased risk of nonmelanoma skin cancers among individuals with Inflammatory bowel disease. Gastroenterology 2011; 141: 1612-20.
147. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009; 58: 1427-36.
148. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with Inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2014; 109: 163-9.
149. Abbas AM, Almukhtar RM, Lofus EV Jr. et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014; 109: 1781-93.
150. Abitbol V, Roux C, Chaussade S et al. Metabolic bone assessment in patients with Inflammatory bowel disease. Gastroenterology 1995; 108: 417-22.
151. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841.
152. Pollak RD, Karmeli F, Eliakim R et al. Femoral neck osteopenia in patients with Inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483-90.
153. Ali T, Lam D, Bronze MS et al. Osteoporosis in Inflammatory bowel disease. Am J Med 2009; 122: 599-604.
154. Vestergaard P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol 2003; 15: 851-6.
155. Lofus EV Jr., Crowson CS, Sandborn WJ et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002; 123: 468-75.
156. Targownik LE, Bernstein CN, Nugent Z et al. Inflammatory bowel disease has a small Effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol 2013; 11: 278-85.
157. Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with Inflammatory bowel disease. Minerva Med 2004; 95: 469-80.
158. Vestergaard P, Krogh K, Rejnmark L et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 176-81.
159. Card T, West J, Hubbard R et al. Hip fractures in patients with Inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004; 53: 251-5.
160. Van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48: 3224-9.
161. Shen B, Remzi FH, Oikonomou IK et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol 2009; 104: 639-46.
162. Compston J, Cooper A, Cooper C et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62: 105-8.
163. Papaioannou A, Morin S, Cheung AM et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864-73.
164. National Osteoporosis Foundation (National Osteoporosis Foundation). Physician's Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation: Washington D.C, 2010.
165. van Staa TP, Leufens HG, Abenhaim L et al. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-11.
166. Somerville KW, Logan RF, Edmond M et al. Smoking and Crohn's disease. Br Med J (Clin Res Ed) 1984; 289: 954-6.
167. Gearry RB, Richardson AK, Frampton CM et al. Population-based cases control study of Inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010; 25: 325-33.
168. Vessey M, Jewell D, Smith A et al. Chronic Inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: fndings in a large cohort study of women of childbearing age. Br Med J (Clin Res Ed) 1986; 292: 1101-3.
169. Halfvarson J, Jess T, Magnuson A et al. Environmental factors in Inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis 2006; 12: 925-33.
170. Mahid SS, Minor KS, Soto RE et al. Smoking and Inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462-71.
171. Lakatos PL, Vegh Z, Lovasz BD et al. Is current smoking still an important environmental factor in Inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 2013; 19: 1010-7.
172. Nunes T, Etchevers MJ, Domenech E et al. Smoking does Influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther 2013; 38: 752-60.
173. Nunes T, Etchevers MJ, Merino O et al. Does smoking Influence Crohn's disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis 2013; 19: 23-9.
174. To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse Effects of tobacco smoking on the natural history of Crohn's disease. Aliment Pharmacol Ther 2016; 43: 549-61.
175. Parsi MA, Achkar JP, Richardson S et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13.
176. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing shortterm and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-7.
177. Domenech E, Carrion S, Garcia-Planella E et al. Smoking status and response to thiopurines in steroid-dependent Inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 971-5.
178. Gustavsson A, Magnuson A, Blomberg B et al. Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease. Aliment Pharmacol Ther 2013; 37: 430-7.
179. Ryan WR, Allan RN, Yamamoto T et al. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004; 187: 219-25.
180. Cosnes J, Beaugerie L, Carbonnel F et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-9.
181. Verschuere S, Allais L, Bracke KR et al. Cigarette smoke and the terminal ileum: increased autophagy in murine follicle-associated epithelium and Peyer's patches. Histochem Cell Biol 2012; 137: 293-301.
182. Doecke JD, Simms LA, Zhao ZZ et al. Smoking behaviour modifes IL23rassociated disease risk in patients with Crohn's disease. J Gastroenterol Hepatol 2015; 30: 299-307.
183. Bergeron V, Grondin V, Rajca S et al. Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. Inflamm Bowel Dis 2012; 18: 1101-11.
184. Benjamin JL, Hedin CR, Koutsoumpas A et al. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 2012; 18: 1092-100.